

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10530963	
	Filing Date		2005-06-21	
	First Named Inventor	Menachem Rubinstein		
	Art Unit	1633		
	Examiner Name	MARVICH, MARIA		
Attorney Docket Number		057878-16		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

Application Number	10530963	10530963 - GAU: 1633
Filing Date	2005-06-21	
First Named Inventor	Menachem Rubinstein	
Art Unit	1633	
Examiner Name	MARVICH, MARIA	
Attorney Docket Number	057878-16	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

1	BAHNER I, et al. "Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes." J Virol. 1993 Jun;67(6):3199-207.	<input type="checkbox"/>
2	BOSHART M, et al. "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus." Cell. 1985 Jun;41(2):521-30.	<input type="checkbox"/>
3	BREGNI M, et al. "Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer." Blood. 1992 Sep 15;80(6):1418-22.	<input type="checkbox"/>
4	BRINSTER RL, et al. "Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs." Cell. 1981 Nov;27(1 Pt 2):223-31.	<input type="checkbox"/>
5	CASSEL A, et al. "Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells." Exp Hematol. 1993 Apr;21(4):585-91.	<input type="checkbox"/>
6	CHAO NJ, et al. "Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy." Blood. 1993 Apr 15;81(8):2031-5.	<input type="checkbox"/>
7	CHEN JD, et al. "Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy." Nature Med. 1997 Oct;3(10):1110-6.	<input type="checkbox"/>
8	COSTANTINI F, and Lacy E. "Introduction of a rabbit beta-globin gene into the mouse germ line." Nature. 1981 Nov 5;294:92-4.	<input type="checkbox"/>
9	COUTURE LA, and Stinchcomb DT. "Anti-gene therapy: the use of ribozymes to inhibit gene function." Trends Genet. 1996 Dec;12(12):510-5.	<input type="checkbox"/>
10	DIGNAM JD, et al. "Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei." Nucleic Acids Res. 1983 Mar 11;11(5):1475-89.	<input type="checkbox"/>
11	DUKEMA R, et al. "Cloning and expression of the chromosomal immune interferon gene of the rat." EMBO J. 1985 Mar;4(3):761-7.	<input type="checkbox"/>

Application Number	10530963	10530963 - GAU: 1633
Filing Date	2005-06-21	
First Named Inventor	Menachem Rubinstein	
Art Unit	1633	
Examiner Name	MARVICH, MARIA	
Attorney Docket Number	057878-16	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

12	DUNBAR CE, et al. "Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation." Blood. 1995 Jun 1;85(11):3048-57.	<input type="checkbox"/>
13	DYNAN WS, and Tjian R. "Control of eukaryotic messenger RNA synthesis by sequence-specific DNA-binding proteins." Nature. 1985 Aug 29-Sep 4;316(6031):774-8.	<input type="checkbox"/>
14	DYNAN WS. "Modularity in promoters and enhancers." Cell. 1989 Jul 14;58(1):1-4.	<input type="checkbox"/>
15	FLETCHER C, et al. "Purification and characterization of OTF-1, a transcription factor regulating cell cycle expression of a human histone H2b gene." Cell. 1987 Dec 4;51(5):773-81.	<input type="checkbox"/>
16	FRIED M, and Crothers DM. "Equilibria and kinetics of lac repressor-operator interactions by polyacrylamide gel electrophoresis." Nucleic Acids Res. 1981 Dec 11;9(23):6505-25.	<input type="checkbox"/>
17	GALE RP, et al. "Blood stem cell transplants come of age." Bone Marrow Transplant. 1992 Mar;9(3):151-5.	<input type="checkbox"/>
18	GORDON S, and WEBB Z. "Secretion of macrophage neutral proteinase is enhanced by colchicine." Proc Natl Acad Sci U S A. 1976 Mar;73(3):872-6.	<input type="checkbox"/>
19	GORMAN CM, et al. "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection." Proc Natl Acad Sci U S A. 1982 Nov;79(22):6777-81.	<input type="checkbox"/>
20	HAO QL, et al. "A functional comparison of CD34 + CD38- cells in cord blood and bone marrow." Blood. 1995 Nov 15;86(10):3745-53.	<input type="checkbox"/>
21	HARBERS K, et al. "Microinjection of cloned retroviral genomes into mouse zygotes: integration and expression in the animal." Nature. 1981 Oct 15;293:540-2.	<input type="checkbox"/>
22	HENON PR, et al. "Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants." Bone Marrow Transplant. 1992 Apr;9(4):285-91.	<input type="checkbox"/>

Receipt date: 09/30/2010

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10530963	10530963 - GAU: 1633
Filing Date	2005-06-21	
First Named Inventor	Menachem Rubinstein	
Art Unit	1633	
Examiner Name	MARVICH, MARIA	
Attorney Docket Number	057878-16	

23	HERZOG RW, et al. "Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus." <i>Proc Natl Acad Sci U S A</i> . 1997 May 27;94(11):5804-9.	<input type="checkbox"/>
24	JUNKER U, et al. "Hematopoietic potential and retroviral transduction of CD34+ Thy-1+ peripheral blood stem cells from asymptomatic human immunodeficiency virus type-1-infected individuals mobilized with granulocyte colony-stimulating factor." <i>Blood</i> . 1997 Jun 15;89(12):4299-306.	<input type="checkbox"/>
25	KEARNS WG, et al. "Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line." <i>Gene Ther</i> . 1996 Sep;3(9):748-55.	<input type="checkbox"/>
26	KOHN DB, et al. "A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children." <i>Blood</i> . 1999 Jul 1;94(1):368-71.	<input type="checkbox"/>
27	LEE SW, et al. "Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain." <i>J Virol</i> . 1994 Dec;68(12):8254-64.	<input type="checkbox"/>
28	LOTTI F, et al. "Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement." <i>J Virol</i> . 2002 Apr;76(8):3996-4007.	<input type="checkbox"/>
29	MALIM MH, et al. "Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function." <i>Cell</i> . 1989 Jul 14;58(1):205-14.	<input type="checkbox"/>
30	MANIATIS T, et al. "Regulation of inducible and tissue-specific gene expression." <i>Science</i> . 1987 Jun 5;236:1237-45.	<input type="checkbox"/>
31	MARASCO WA. "Intrabodies: turning the humoral immune system outside in for intracellular immunization." <i>Gene Ther</i> . 1997 Jan;4(1):11-5.	<input type="checkbox"/>
32	MCKNIGHT S, and Tjian R. "Transcriptional selectivity of viral genes in mammalian cells." <i>Cell</i> . 1986 Sep 12;46(6):795-805.	<input type="checkbox"/>
33	MIYOSHI H, et al. "Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors." <i>Science</i> . 1999 Jan 29;283:682-6.	<input type="checkbox"/>

Application Number	10530963	10530963 - GAU: 1633
Filing Date	2005-06-21	
First Named Inventor	Menachem Rubinstein	
Art Unit	1633	
Examiner Name	MARVICH, MARIA	
Attorney Docket Number	057878-16	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

34	MORITZ T, et al. "Human cord blood cells as targets for gene transfer: potential use in genetic therapies of severe combined immunodeficiency disease." J Exp Med. 1993 Aug 1;178(2):529-36.	<input type="checkbox"/>
35	MÜHL H, et al. "Interferon-gamma mediates gene expression of IL-18 binding protein in nonleukocytic cells." Biochem Biophys Res Commun. 2000 Jan 27;267(3):960-3.	<input type="checkbox"/>
36	MURPHY JE, et al. "Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin." Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13921-6.	<input type="checkbox"/>
37	NEIGHBORS M, et al. "A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on Interferon gamma production." J Exp Med. 2001 Aug 6;194(3):343-54.	<input type="checkbox"/>
38	NOVICK D, et al. "Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response." Immunity. 1999 Jan;10(1):127-36.	<input type="checkbox"/>
39	NOVICK D, et al. "A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18." Cytokine. 2001 Jun 21;14(6):334-42.	<input type="checkbox"/>
40	PALMITER RD, and Brinster RL. "Germ-line transformation of mice." Annu Rev Genet. 1986;20:465-99.	<input type="checkbox"/>
41	REVZIN A. "Gel electrophoresis assays for DNA-protein interactions." Biotechniques. 1989 Apr;7(4):346-55.	<input type="checkbox"/>
42	SASSONE-CORSI, P. & BORRELLI, E., "Transcriptional regulation by trans-acting factors." Trends in Genetics Volume 2, 1986, Pages 215-219.	<input type="checkbox"/>
43	SCHEIDERIT C, et al. "Identification and purification of a human lymphoid-specific octamer-binding protein (OTF-2) that activates transcription of an immunoglobulin promoter in vitro." Cell. 1987 Dec 4;51(5):783-93.	<input type="checkbox"/>
44	SLOBOD KS, et al. "Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults." Blood. 1996 Nov 1;88(9):3329-35.	<input type="checkbox"/>

Receipt date: 09/30/2010

Application Number	10530963	10530963 - GAU: 1633
Filing Date	2005-06-21	
First Named Inventor	Menachem Rubinstein	
Art Unit	1633	
Examiner Name	MARVICH, MARIA	
Attorney Docket Number	057878-16	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

45	SNYDER RO, et al. "Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors." Nature Genet. 1997 Jul;16(3):270-6.	<input type="checkbox"/>
46	SNYDER RO, et al. "Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors." Nature Med. 1999 Jan;5(1):64-70.	<input type="checkbox"/>
47	SONG S, et al. "Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors." Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14384-8.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

Receipt date: 09/30/2010

Application Number	10530963	10530963 - GAU: 1633
Filing Date	2005-06-21	
First Named Inventor	Menachem Rubinstein	
Art Unit	1633	
Examiner Name	MARVICH, MARIA	
Attorney Docket Number	057878-16	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.16. Please see CFR 1.4(d) for the form of the signature.

Signature	/Leena H. Karttunen/	Date (YYYY-MM-DD)	2010-09-30
Name/Print	Leena H. Karttunen	Registration Number	60335

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M./